• Successful $16.8m capital raising via placement and share purchase plan
• Funds to support execution of CY2026 initiatives, including Alzheimer's trial
• Cash runway extended beyond topline results of pivotal Alzheimer's trial

Actinogen Medical (ASX: ACW) has announced the successful completion of a $16.8 million capital raising, comprising a $12 million placement and a $4.8 million share purchase plan (SPP). The SPP was offered to all eligible existing shareholders on the same terms as the placement, with an offer price of $0.042 per share. Approximately 114 million new shares will be issued to SPP participants. The completion of this funding round, together with other funding sources, gives the company a proforma 31 December 2025 cash balance of $29.5 million. This allows Actinogen to successfully execute on its CY2026 planned initiatives, including commencement of an Open Label Extension study, completing other non-clinical activities and completing the pivotal XanaMIA phase 2b/3 Alzheimer's disease trial by November 2026. The company's CFO, Mr Will Souter, stated that the successful placement and SPP provide Actinogen with a cash runway extending beyond the topline final results of the pivotal Alzheimer's trial, anticipated in November 2026.

The successful $16.8 million capital raising provides Actinogen with a proforma 31 December 2025 cash balance of $29.5 million, allowing the company to execute on its CY2026 planned initiatives, including the pivotal XanaMIA Alzheimer's disease trial.